Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysis of our departmental database in histologically proven, HIV-negative KS. Results: Fifty-eight patients treated with intravenous paclitaxel 100 mg weekly were identified. Among these patients, 11 patients underwent paclitaxel as first-line treatment, whereas 47 received paclitaxel after other types of systemic chemotherapy. Fifty-three (94.6%) patients achieved a partial or a complete remission after a mean of 13.5 infusions. Disease progression was observed in two patients and one patient had a stable disease. Thirty-one (58.5%) of 53 responding patients are still stable after a mean of 19.1 months of follow-up, while 22 (41.5%) patients relapsed after a mean of 14 months. Paclitaxel was repeated in relapsed patients obtaining PR/CR in all cases. Tolerance was good except for one patient who discontinued the treatment because of a severe allergic reaction. Conclusion: Paclitaxel is effective for the treatment of non-HIV-related KS, both as first- and as second-line treatment. It is well tolerated and can be repeated without loss of efficacy.

Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients / A. Tourlaki, F. Germiniasi, L.C. Rossi, S. Veraldi, L. Brambilla. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2019). [Epub ahead of print] [10.1080/09546634.2019.1590520]

Paclitaxel as first- or second-line treatment for HIV-negative Kaposi’s sarcoma: a retrospective study of 58 patients

Tourlaki A.;Germiniasi F.;Rossi L. C.;Veraldi S.;
2019

Abstract

Background: Paclitaxel has recently been approved for AIDS-related Kaposi’s sarcoma (KS) and there is much interest also in HIV-negative KS. Objective: To assess the safety and effectiveness of intravenous paclitaxel in the treatment of non-HIV-associated KS. Method: A retrospective database analysis of our departmental database in histologically proven, HIV-negative KS. Results: Fifty-eight patients treated with intravenous paclitaxel 100 mg weekly were identified. Among these patients, 11 patients underwent paclitaxel as first-line treatment, whereas 47 received paclitaxel after other types of systemic chemotherapy. Fifty-three (94.6%) patients achieved a partial or a complete remission after a mean of 13.5 infusions. Disease progression was observed in two patients and one patient had a stable disease. Thirty-one (58.5%) of 53 responding patients are still stable after a mean of 19.1 months of follow-up, while 22 (41.5%) patients relapsed after a mean of 14 months. Paclitaxel was repeated in relapsed patients obtaining PR/CR in all cases. Tolerance was good except for one patient who discontinued the treatment because of a severe allergic reaction. Conclusion: Paclitaxel is effective for the treatment of non-HIV-related KS, both as first- and as second-line treatment. It is well tolerated and can be repeated without loss of efficacy.
chemotherapy; intravenous paclitaxel; Kaposi’s sarcoma; taxanes; treatment
Settore MED/35 - Malattie Cutanee e Veneree
apr-2019
THE JOURNAL OF DERMATOLOGICAL TREATMENT
Article (author)
File in questo prodotto:
File Dimensione Formato  
Tourlaki-Germiniasi-Rossi-Veraldi-Brambilla (J Dermatolog Treat in press 2019).pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 710.87 kB
Formato Adobe PDF
710.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/652547
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact